Abstract: ObjectiveTo analysis the toxicities and efficacy of gemcitabine combined with cisplatin on metastatic breast cancer(MBC). Methods Thirty-three MBC patients,who pretreated with anthracycline- and Taxane-based chemotherapy,received gemcitabine (1000 mg/m2 by intravenous infusion on d1~d8) and cisplatin (25 mg/m2 by intravenous infusion on d1~d3) every 3 weeks.Response evaluation was performed every second cycle and toxicity was observed every week. Results A complete response(CR) was seen in 3 patients(9.7%),partial response (PR) was seen in 10 patients (32.3%),stable disease (SD) was seen in 7 patients (22.6%) and progressive disease (PD) was seen in 11 patients (35.4%).The response rate(RR) was 42%.The median progression-free survival(PFS) was 4.8 months(range,1~11.8 months).The most frequent side effects were hematologic and gastrointestinal adverse events.No treatment related death occurred. Conclusion The combination of gemcitabine and cisplatin appears to be effective and is safe and tolerable for patients with anthracycline- and taxane-pretreated MBC.